Introduction {#Sec1}
============

A major research question in Quantitative Structure--Activity Relationship (QSAR) has been (and still is) how to numerically encode small molecules \[[@CR1]--[@CR4]\]. Compound descriptors are generally calculated using 2-dimensional (2D) or 3-D representations of chemical structures as a starting point (although sometimes even simpler 1-D descriptors are also used, e.g., atom counts or molecular weight \[[@CR5], [@CR6]\]). The underlying idea when these descriptors are used to generate QSAR models is the 'Molecular Similarity Principle', which states that the bioactivities of structurally similar compounds tend to be correlated more often than those of dissimilar ones \[[@CR7], [@CR8]\]. Although compound descriptors based on the chemical structure are customarily used today in similarity searching and QSAR, they suffer from the limitation that they can only provide accurate predictions for structurally similar compounds, where the above principle holds. However, in case of e.g., 'activity cliffs' \[[@CR9]\], different scaffolds binding to the same protein, or different binding sites, there are exceptions to this principle, and molecular descriptors based purely on molecular structure will not be sufficiently information-rich in order to handle such multi-modal models very well. Hence, the information that can be gathered about the bioactivities of structurally dissimilar compounds on the basis of their chemical structure alone is often limited.

A conceptually different approach is the quantification of compound similarity on the basis of the similarity of their bioactivity profiles instead of the similarity of their chemical structures \[[@CR10]--[@CR12]\]. The underlying principle, *similarity in bioactivity space*, is that compounds displaying correlated bioactivity endpoints across a set of assays (e.g., assays based on the activity of a purified protein, or cell-based assays) are likely to display similar activities also on other assays (which conceptually can then be modelled as a linear combination, or more complex function, of the input assay panel activities \[[@CR13]\]). The set of bioactivities across a panel of assays are usually known as affinity, bioactivity, protein or high-throughput screening fingerprints \[[@CR12]--[@CR15]\]. Note that the term 'affinity fingerprint' is often used even when the bioactivity endpoints are not K~i~ nor K~d~ values, but rather assay-specific metrics of potency, such as IC~50~ or EC~50~ values, so it comprises a broad set of activity spectra-based descriptors. In the following and in the accompanying manuscript, we use the term affinity fingerprint to refer to the set of biological endpoints, experimentally determined or predicted, irrespective of whether the endpoint measured corresponds to a potency or an affinity metric. For a comprehensive review of existing methods to predict affinity fingerprints using existing high-throughput data \[[@CR16]--[@CR28]\], the reader is referred to the introduction of the accompanying manuscript \[[@CR29]\].

Affinity fingerprints encode information about the many interactions (both strong and weak) between a given compound and its targets, and thus permit to model complex biological endpoints, such as human toxicity and in vitro cancer cell line sensitivity, and provide complementary signal to chemical structure information \[[@CR30], [@CR31]\]. Current predictive methods use either structural information of compounds as descriptors to model their activity on a single target (i.e., QSAR \[[@CR32]\]), or assay activity as covariates to model the activity of a single compound across a target panel \[[@CR33]--[@CR35]\]. The latter strategy suffers from the limitation that in order to make predictions on novel targets these need to be experimentally profiled in the same way as those in the training set. In contrast, QSAR methods permit, to the extent the training data allows extrapolation in chemical space \[[@CR36]\], to make predictions on new molecules more scalable, as the computation of compound descriptors only requires the chemical structure as input. Therefore, designing computational tools to model assay readouts using the chemical structure of compounds as input would permit to predict in silico the affinity fingerprint for a molecule of interest without the need for experimental testing, which in turn could provide a better description of the relevant variance connecting chemical and biological space.

The construction of such in silico affinity fingerprints, termed QSAR-derived Quantitative Affinity Fingerprints (QAFFPs), is described in the accompanying manuscript \[[@CR29]\] where their performance for similarity searching, compound activity classification and scaffold hopping is reported. The range of application of QAFFP is further enhanced in the present manuscript, in which the use of QAFFPs in regression settings is studied. Specifically, QAFFPs were assessed to model in vitro potency on a continuous scale across 43 diverse data sets (Fig. [1](#Fig1){ref-type="fig"} and Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). For each compound in each data set, the predictions generated by a set of 1360 QSAR models (termed base models) trained on IC~50~, EC~50~, K~i~ and K~d~ data were recorded. These vectors of predicted activities, i.e., QAFFP, were then used as compound descriptors to build QSAR models. To benchmark the predictive power of QAFFP, we assembled 18 diverse cytotoxicity data sets from ChEMBL, and constructed QSAR models using cross-validation. In addition, we also used 25 additional protein target QSAR data sets from ChEMBL for validation. The compounds were encoded using either circular Morgan fingerprints \[[@CR37]\], 1-D and 2-D physicochemical descriptors, or QAFFP fingerprints. Hence, this framework allowed us to evaluate the predictive power of QAFFP fingerprints across a wide range of bioactivity prediction models.Fig. 1Overview of the workflow used in this study. We initially assembled and modelled 1360 data sets from ChEMBL database using RF (Random Forest) and conformal prediction. Of these, 440 displayed high predictive power in cross validation (q^2^ \> 0.5) and on external molecules (R^2^~test\ set~ \> 0.6), and hence, were selected to build QAFFP fingerprints for 18 cytotoxicity and 25 protein target data sets (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}) assembled from ChEMBL database as well. To benchmark the predictive signal of QAFFP, we compared the performance of RF models trained on QAFFP against models generated using Morgan2 fingerprints or 1-D and 2-D physicochemical descriptors across a diverse set of 43 bioactivity data sets (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"})Table 1Cytotoxicity data sets used in this studyCell lineCell line descriptionChEMBL assay IDCellosaurus IDOrganism of originNumber of bioactivity data pointsA2780Ovarian carcinoma cellsCHEMBL3308421CVCL_0134Homo sapiens2255CCRF-CEMT-cell leukemiaCHEMBL3307641CVCL_0207Homo sapiens3047DU-145Prostate carcinomaCHEMBL3308034CVCL_0105Homo sapiens2512HCT-116Colon carcinoma cellsCHEMBL3308372CVCL_0291Homo sapiens6231HCT-15Colon adenocarcinoma cellsCHEMBL3307945CVCL_0292Homo sapiens994HeLaCervical adenocarcinoma cellsCHEMBL3308376CVCL_0030Homo sapiens7532HepG2Hepatoblastoma cellsCHEMBL3307718CVCL_0027Homo sapiens3897HL-60Promyeloblast leukemia cellsCHEMBL3307654CVCL_0002Homo sapiens4637HT-29Colon adenocarcinoma cellsCHEMBL3307768CVCL_0320Homo sapiens5630K562Erythroleukemia cellsCHEMBL3308378CVCL_0004Homo sapiens4160KBSquamous cell carcinomaCHEMBL3307959CVCL_0372Homo sapiens2731L1210Lymphocytic leukemia cellsCHEMBL3308391CVCL_0382Mus musculus4873LoVoColon adenocarcinoma cellsCHEMBL3307691CVCL_0399Homo sapiens1120MCF7Breast carcinoma cellsCHEMBL3308403CVCL_0031Homo sapiens12,001MDA-MB-231Breast epithelial adenocarcinoma cellsCHEMBL3307960CVCL_0062Homo sapiens3482NCI-H460Non-small cell lung carcinomaCHEMBL3307677CVCL_0459Homo sapiens2277PC-3Prostate carcinoma cellsCHEMBL3307570CVCL\_ NIRG---MRC0035Homo sapiens4294SK-OV-3Ovarian carcinoma cellsCHEMBL3307746CVCL_0532Homo sapiens1589Table 2Protein target data sets used in this studyTarget preferred nameTarget abbreviationUniprot IDChEMBL IDNumber of bioactivity data pointsAlpha-2a adrenergic receptorA2aP08913CHEMBL1867203Tyrosine-protein kinase ABLABL1P00519CHEMBL1862773AcetylcholinesteraseAcetylcholinesteraseP22303CHEMBL2203159Androgen ReceptorAndrogenP10275CHEMBL18711290Serine/threonine-protein kinase Aurora-AAurora-AO14965CHEMBL47222125Serine/threonine-protein kinase B-rafB-rafP15056CHEMBL51451730Cannabinoid CB1 receptorCannabinoidP21554CHEMBL2181116Carbonic anhydrase IICarbonicP00918CHEMBL205603Caspase-3CaspaseP42574CHEMBL23341606ThrombinCoagulationP00734CHEMBL2041700Cyclooxygenase-1COX-1P23219CHEMBL2211343Cyclooxygenase-2COX-2P35354CHEMBL2302855Dihydrofolate reductaseDihydrofolateP00374CHEMBL202584Dopamine D2 receptorDopamineP14416CHEMBL217479Norepinephrine transporterEphrinP23975CHEMBL2221740Epidermal growth factor receptor erbB1erbB1P00533CHEMBL2034868Estrogen receptor alphaEstrogenP03372CHEMBL2061705Glucocorticoid receptorGlucocorticoidP04150CHEMBL20341447Glycogen synthase kinase-3 betaGlycogenP49841CHEMBL2621757HERGHERGQ12809CHEMBL2405207Tyrosine-protein kinase JAK2JAK2O60674CHEMBL29712655Tyrosine-protein kinase LCKLCKP06239CHEMBL2581352Monoamine oxidase AMonoamineP21397CHEMBL19511379Mu opioid receptorOpioidP35372CHEMBL233840Vanilloid receptorVanilloidQ8NER1CHEMBL47941923

Methods {#Sec2}
=======

Data collection and curation {#Sec3}
----------------------------

We gathered IC~50~ data for 18 cancer cell lines from ChEMBL database version 23 using the *chembl_webresource_client* python module \[[@CR38]--[@CR40]\]. To gather high-quality data, we only kept IC~50~ values corresponding to molecules that satisfied the following filtering criteria \[[@CR41]\]: (i) molecule type equal to "Small molecule", (ii) activity unit equal to "nM", and (iii) activity relationship equal to "=". The average pIC~50~ value was calculated when multiple IC~50~ values were annotated for the same compound-cell line pair. IC~50~ values were modeled in a logarithmic scale (pIC~50~ = − log~10~ IC~50~ \[M\]). Further information about the data sets is given in Table [1](#Tab1){ref-type="table"} and in a previous study by the authors \[[@CR42]\]. We also collected 25 QSAR data sets for validation from previous work by the authors (Table [2](#Tab2){ref-type="table"}) \[[@CR42]--[@CR44]\]. All data sets used in this study, as well as the code required to generate the results presented herein, are publicly available at <https://github.com/isidroc/QAFFP_regression>. The distribution of bioactivity values for all data sets is reported in Additional file [1](#MOESM1){ref-type="media"}: Figure S1.

Molecular representation {#Sec4}
------------------------

The Innovative Medicines Initiative eTOX project standardizer (<https://github.com/flatkinson/standardiser>) was used to normalize all chemical structures reported here to a common representation scheme using the default options. This normalization step is crucial for the generation of compound descriptors, as these (except for e.g., heavy atom counts) generally depend on a consistent representation of molecular properties, such as aromaticity of ring systems, tautomer representation or protonation states. Entries corresponding to entirely inorganic structures were removed. In the case of organic molecules, the largest fragment was kept in order to filter out counterions following standard procedures in the field \[[@CR45], [@CR46]\], and salts were neutralized.

QSAR-based activity fingerprints (QAFFP) {#Sec5}
----------------------------------------

The protocol to calculate QSAR-based affinity fingerprints using ChEMBL data is explained in detail in the accompanying manuscript \[[@CR29]\]. In brief, the workflow can be summarized in the following five steps (Fig. [1](#Fig1){ref-type="fig"}):We initially gathered a total of 1360 QSAR data sets from ChEMBL version 19. We considered both human and non-human protein targets, and EC~50~ (173 targets), IC~50~ (786), K~i~ (365), and K~d~ (36) values as bioactivity endpoints. We only considered measurements with an activity relationship equal to '=' and activity values reported in 'nM' units. The mean value was used as the activity value when multiple measurements were annotated for the same compound-protein pair only if the standard deviation of all annotated measurements was lower than 0.5; otherwise the data point was not further considered.To model these data sets, we trained tenfold CV RF models using 30% of the data as the test set, and Morgan2 fingerprints as compound descriptors. We term these models *base models*. A total of 440 models (376 unique targets) displayed an average R^2^~test~ value \> 0.6, and a cross-validation q^2^ value \> 0.5. These cut-off values are a reasonable choice to identify models with high predictive power on unseen data (although we note that the minimum predictive power required for a model to be useful in practice depends on the context in which it is applied, e.g., poor predictive performance might be useful in hit identification but not in lead optimization) \[[@CR47]\].The cross-validation predictions served to build a cross-conformal predictor for each of the 1360 base models as previously described \[[@CR48]\].To calculate QAFFP for the compounds in the 18 cytotoxicity and 25 protein target data sets, we used the base models to calculate point predictions (i.e., IC~50~, EC~50~, K~d~, and K~i~ values), and calculated confidence intervals (90% confidence) for each individual prediction using the corresponding conformal predictor. Hence, for a given compound we computed (i) a 1360-dimensional fingerprint, where each bit corresponds to the predicted activity for that compound using one of the 1360 base models considered, and (ii) a 1360-dimensional vector recording the prediction errors calculated using conformal prediction.Next, we combined the point predictions and the predicted confidence intervals to define three types of QAAFP (Fig. [1](#Fig1){ref-type="fig"}):Real-valued QAFFP (rv-QAFFP): This type of fingerprint is defined by the point predictions computed using the base models. We defined two types of rv-QAFFP fingerprints: "rv-QAFFP 440" fingerprints were computed using the 440 base models showing high predictive power on unseen data as explained above, whereas "rv-QAFFP 1360" fingerprints were calculated using the 1360 base models irrespective of their predictive power on the test set.Binary QAFFP (b-QAFFP 440): To construct "b-QAFFP 440" fingerprints we set to one 1 all positions in the rv-QAFFP 440 fingerprint corresponding to predictions lying above a given activity cutoff (in this case 5 pIC~50~ units), and which are within the applicability domain (AD) of the underlying base model. We consider that a prediction is within the AD of a base model if the predicted confidence interval is lower than 2 pIC~50~ units, (i.e., the predicted confidence interval is no wider than +/− 2). Thus, all values that lie below the affinity cutoff but are still within model AD were encoded using zeros. The value was set to zero as well for predictions lying outside the model AD, following the assumption that a compound is more likely to be inactive than active. Thus, this corresponds to setting to one those bits corresponding to the targets with which a given compound is predicted to interact even at low compound concentrations, while also taking into account the confidence of the prediction.

In the case of the 25 protein target data sets (Table [2](#Tab2){ref-type="table"}), base models trained on bioactivity data from these targets or their orthologues were excluded, and thus not considered to compute QAFFP for these data sets.

As a baseline method for comparisons, we considered RF models trained on Morgan fingerprints \[[@CR37]\], and physicochemical descriptors. We computed circular Morgan fingerprints using RDkit (release version 2013.03.02) \[[@CR37], [@CR49]\]. The radius was set to 2 and the fingerprint length to 1024. Thus, we refer to Morgan fingerprints as Morgan2 hereafter. Morgan fingerprints encode compound structures by considering radial atom neighborhoods. The choice of Morgan fingerprints as a base line method to compare the performance of QSAR-derived affinity fingerprints was motivated by the high retrieval rates obtained with Morgan fingerprints in benchmarking studies of compound descriptors \[[@CR50], [@CR51]\]. A total of 200 1-D and 2-D physicochemical descriptors (abbreviated as Physchem hereafter) were also computed using RDkit and used to generate QSAR models. We also combined Morgan2 fingerprints, physicochemical descriptors, and QAFFP to define combined descriptors, namely: rv-QAFFP 440 and Morgan2, rv-QAFFP 440 and Physchem, b-QAFFP 440 and Morgan2, b-QAFFP 440 and Physchem, rv-QAFFP 1360 and Morgan2, rv-QAFFP 1360 and Physchem. Thus, we considered a total of 11 types of descriptors to encode the compounds.

The Jaccard-Needham dissimilarity between pairs of compounds was computed using the function *scipy.spatial.distance.jaccard* from the python library SciPy \[[@CR52]\].

Model training and performance evaluation {#Sec6}
-----------------------------------------

We trained Random Forest (RF) models using tenfold CV on 70% of the data selected at random. The performance was evaluated on the remaining 30% of the data (i.e., test set) by calculating the root mean squared error (RMSE) and the Pearson correlation coefficient (R^2^) for the observed against the predicted pIC~50~ values. We trained 50 models for all combinations of factor levels, giving rise to 23,650 models (43 data sets × 11 descriptors sets × 50 replicates). In each replicate, a different subset of the data was selected as the test set. The composition of the training and test sets across the 50 replicates for a given data set was the same for all fingerprint types. RF models and feature importance values were computed using the *RandomForestRegressor* class from the python library Scikit-learn \[[@CR53]\].

RF are generally robust across a wide range of parameter values. In practice, a suitable choice for the number of trees in the Forest (*n*~trees~) was shown to be 100 in previous work \[[@CR54]--[@CR56]\], as higher values do not generally lead to significantly higher predictive power, which we found to be also the case for these data sets (Additional file [1](#MOESM1){ref-type="media"}: Figure S2). Hence, we trained the RF models using 100 trees and the default values for all other parameters.

Experimental design {#Sec7}
-------------------

To benchmark the predictive power of QAFFP, Morgan2 fingerprints and physicochemical descriptors in a statistically robust manner we designed a balanced fixed-effect full-factorial experiment with replications \[[@CR57]\]. We considered two factors, namely: (i) *data set*: 43 data sets considered, and (ii) *descriptor*: rv-QAFFP 440, b-QAFFP 440, rv-QAFFP 1360, Morgan2, Physchem, rv-QAFFP 440 and Morgan2, rv-QAFFP 440 and Physchem, b-QAFFP 440 and Morgan2, b-QAFFP 440 and Physchem, rv-QAFFP 1360 and Morgan2, rv-QAFFP 1360 and Physchem. In addition, we included an interaction term between the factors descriptor and data set to examine whether the performance of the descriptor types used vary across data sets.
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                \begin{document}$${\upepsilon _{i,j,k}} = {\text{RMSE}}_{i,j,k}-{\text{mean}} ({\text{RMSE}}_{i,j})$$\end{document}$. These errors are assumed to (i) be mutually independent, (ii) have an expectation value of zero, and (iii) have constant variance. The use of a linear model to assess the predictive power of QAFFPP, Morgan2 fingerprints and Physchem descriptors allowed to control for the variability across data sets, and to avoid that results were biased by elements such as the number of datapoints, data set modellability, etc.

The normality and homoscedasticity assumptions of the linear model were assessed with (i) quantile--quantile (Q--Q) plots and (ii) by visual inspection of the RMSE~test~ distributions, and (iii) by plotting the fitted RMSE~test~ values against the residuals \[[@CR57]\]. Homoscedasticity means that the residuals are evenly distributed (i.e., equally dispersed) across the range of the RMSE~test~ values considered in the linear model. It is essential to examine this assumption to guarantee that the modeling errors (i.e., residuals) and the dependent variable are not correlated. A systematic bias of the residuals would indicate that they are not consistent with random error, and hence, they contain predictive information that should be included in the model.

Results and discussion {#Sec8}
======================

We initially sought to examine the differences between Morgan2 fingerprints and QAFFP in terms of how they encode the chemical space. To this aim, for each pair of compounds in the 18 cytotoxicity data sets considered (Table [1](#Tab1){ref-type="table"}) we computed pairwise Jaccard-Needham dissimilarity values \[[@CR52], [@CR58]\] using Morgan2 fingerprints (similarity in chemical space; x-axis in Fig. [2](#Fig2){ref-type="fig"}), and pairwise Pearson correlation coefficients using rv-QAFFP 440 fingerprints (similarity in bioactivity space; y-axis in Fig. [2](#Fig2){ref-type="fig"}). Overall, we observe a negative and significant correlation (Pearson correlation, *P* \< 0.001) between Jaccard-Needham dissimilarity and correlation in bioactivity space for all data sets. The pairwise correlation values calculated using rv-QAFFP are, as expected, highly correlated for pairs of structurally similar compounds (i.e., showing a low Jaccard-Needham dissimilarity; upper left-hand quadrant in the panels in Fig. [2](#Fig2){ref-type="fig"}). These results are consistent with the fact that QAFFP are computed using base models trained on Morgan2 fingerprints and with the similarity principle, as structurally similar compounds are expected to show correlated bioactivity profiles. A substantial fraction of compound pairs showing a relatively large degree of structural dissimilarity (Jaccard-Needham dissimilarity \~ 1) show high similarity in bioactivity space (upper right-hand quadrant in Fig. [2](#Fig2){ref-type="fig"}). For instance, compounds CHEMBL357519 and CHEMBL9011 (first row in Fig. [3](#Fig3){ref-type="fig"}) display comparable activities on the cell line KB (pIC~50~ = 6.57 and 7.56, respectively), and a Jaccard-Needham dissimilarity of 0.87. However, their rv-QAFFPs are highly correlated, with a Pearson correlation coefficient of 0.84 (*P* \< 0.05). Another example is the pair of compounds CHEMBL31400 and CHEMBL1801792 in the HeLa data set (second row in Fig. [3](#Fig3){ref-type="fig"}), with pIC~50~ values of 7.16 and 7.10, respectively, a Jaccard-Needham dissimilarity of 0.86, and highly correlated rv-QAFFP 440 values (Pearson R^2^ = 0.80, *P *\< 0.05). Overall, these results show that structurally dissimilar compounds displaying comparable pCI~50~ values (given the uncertainty of pIC~50~ data \[[@CR41]\]) are often clustered closely in bioactivity space, as quantified by the correlation between their rv-QAFFP 440 values. This is also allowed according to the 'Neighbourhood Behavior' principle \[[@CR59]\], which states that while similar molecules are expected to behave similarly or average, dissimilar molecules may display either dissimilar, but in some cases also similar properties.Fig. 2Jaccard-Needham dissimilarity calculated using Morgan2 fingerprints, against Pearson correlation values calculated using rv-QAFFP 440 for all pairs of compounds in each data set. Only a randomly picked subset of the 18 cytotoxicity data sets is shown for illustration. Similar results were obtained for the other data setsFig. 3Examples of structurally dissimilar compounds, showing correlated rv-QAFFP 440 and similar pIC~50~ values. These examples illustrate that the similarity in bioactivity space is captured by the rv-QAFFP 440 even for structurally dissimilar compounds, underlining the importance of using multi-modal representations of chemical structures, beyond similarity in chemical descriptor space alone

To test whether encoding compounds using rv-QAFFP improves the modeling of compound activity, we generated RF models for the 18 cytotoxicity data sets (Table [1](#Tab1){ref-type="table"}), as well as for 25 protein target data sets (Table [2](#Tab2){ref-type="table"}) \[[@CR42]\]. As a baseline for comparisons, we trained RF models using Morgan2 fingerprints or physicochemical descriptors, and quantified performance by calculating the RMSE and R^2^ values for the observed against the predicted pIC~50~ values for the compounds in the test set (Fig. [4](#Fig4){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S3). The average R^2^~test~ values (*n *= 50) were above 0.6 for all data sets, indicating that Morgan2 fingerprints and physicochemical descriptors capture the aspects of molecular structure related to bioactivity, and hence permit to model compound activity for these data sets satisfactorily.Fig. 4RMSE~test~ values calculated with models trained on each of the 11 descriptor types considered across the 43 data sets modelled in this study (18 cytotoxicity and 25 protein data sets; Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). We trained 50 models for each combination of descriptor type and data set, each time holding a different subset of the data as test set. Overall, predictive models were obtained for all descriptor types, and the performance of different descriptor types varied across data sets modelled

We used the same modeling strategy to generate RF models using three types of QAFFP (b-QAFFP 440, rv-QAFFP 440, and rv-QAFFP 1360), and QAFFPs combined with Morgan2 fingerprints and physicochemical descriptors (see "[Methods](#Sec2){ref-type="sec"}"). Overall, the models trained on QAFFP showed high predictive power, with R^2^ values in the 0.5--0.9 range, and RMSE values in the \~ 0.6--0.95 pIC~50~ units range (Fig. [4](#Fig4){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S3). These values are in agreement with the expected model performance given the uncertainty of pIC~50~ data from ChEMBL; i.e., the maximum Pearson correlation coefficient when modeling IC~50~ data from ChEMBL, which was estimated to be in the 0.51--0.85 range \[[@CR41], [@CR60]\]. Finally, we performed Y-scrambling experiments for all data sets \[[@CR61]\]. To this aim, we shuffled the bioactivity values for the training set instances before model training. We obtained R^2^ values around 0 (P \< 0.001) in all Y-scrambling experiments we performed (Additional file [1](#MOESM1){ref-type="media"}: Figure S4). Therefore, these results indicate that the predictive power of the models trained on QAFFP is not a consequence of spurious correlations.

To assess the relative performance of the 11 descriptor types defined in a statistically robust manner, we designed a factorial experiment (see "[Methods](#Sec2){ref-type="sec"}"). The fitted linear model displayed an R^2^ value adjusted for the number of parameters equal to 0.90, and a standard error for the residuals equal to 0.03 (*P* \< 10^−15^), indicating that the variability of model performance on the test set can be explained to a large extent by the data set and descriptor type used. The values for the coefficients, namely slopes and intercept, and their *P* values are reported in Additional file [2](#MOESM2){ref-type="media"}: Table S1. The verification of the model assumptions is reported in Fig. [5](#Fig5){ref-type="fig"}. We did not include the percentage of the data included in the test set as a covariate in the linear model because we observed that the relative performance of the descriptor types considered was overall constant across models trained on increasingly larger fractions of the data (Additional file [1](#MOESM1){ref-type="media"}: Figure S5).Fig. 5Verification of the linear model assumptions. **a** Assumption of homoscedasticity of the residuals. Fitted values against the residuals. The residuals are centered around zero and, roughly, present a comparable dispersion across the range of values considered, indicating that the assumption of the homoscedasticity of the residuals is fulfilled. Assumption of the normality of the residuals, assessed with the distribution of the residuals (**b**) and a quantile--quantile (Q--Q) plot (**c**). The residuals follow a Gaussian distribution with zero mean, indicating that the assumption of the normality of the residuals is fulfilled. Overall, these results indicate that the assumptions of the linear model are fulfilled

The factorial analysis revealed a significant interaction between the factors *data set* and *descriptor type* (*P* \< 10^−15^) indicating that the predictive power of the descriptor types considered varies across data sets. This can be observed in Fig. [4](#Fig4){ref-type="fig"} as well, as the distances between the boxes vary across data sets; i.e., a given descriptor type leads to the highest predictive power for some data sets but not in others. For instance, the average RMSE value for rv-QAFFP 440 (red box) is higher than that corresponding to Morgan2 fingerprints (light blue box) when modeling the cell line data set A2780; however, the opposite is observed for the data set Cannabinoid (first panel in Fig. [4](#Fig4){ref-type="fig"}). Interestingly, combining Morgan2 fingerprints and QAFFP did not increase model performance, and models trained on the binary form of QAFFP (b-QAFFP) constantly led to lower predictive power as compared to rv-QAFFP (Fig. [4](#Fig4){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S3). Overall, these results suggest that the predictive signal provided by both fingerprints, at least when using RF, does not seem to be complementary.

Given the substantial diversity in performance of the 1360 base models used to generate QAFFP \[[@CR29]\], we next sought to investigate whether we could better model the 18 cytotoxicity data sets by computing rv-QAFFP using only those base models showing high predictive power. To this end, we used increasingly higher cut-off values for the minimum R^2^~test~ value a base model needs to show to be considered for the calculation of rv-QAFFP. That is, we hypothesized that removing from the rv-QAFFP those bits corresponding to moderately predictive base models might lead to a less noisy rv-QAFFP and a better description of the relevant variance connecting chemical and biological space, thus increasing predictive power. We found that rv-QAFFP built using base models with R^2^~test~ \> 0.60--0.65 lead to the lowest average RMSE~test~ values for the 18 cytotoxicity data sets (Fig. [6](#Fig6){ref-type="fig"}). Models trained on rv-QAFFP values generated with highly predictive base models (R^2^~test~ \> 0.8) only, leaving 76 based models to compute QAFFP, increased the average RMSE~test~ values by \~ 12--20%. One explanation for this might be that increasing the dimensionality of the QAFFP by including low predictive base models adds predictive signal, even if these generate inaccurate predictions \[[@CR13]\]. However, we observed that including all 1360 base models to compute QAFFP (i.e., rv-QAFFP 1360) did not increase predictive power on the test set, indicating that base models with low predictive power do not add additional predictive signal (Fig. [7](#Fig7){ref-type="fig"}). It is also important to consider that RF models are generally robust to moderate noise levels when modeling QSAR data sets, and hence, low levels of noise are well tolerated, and, in fact, might even help to generate models robust to noisy input data \[[@CR62], [@CR63]\]. Together, these results indicate that although the predictions generated by moderately predictive base models might be noisy, they better explain the relevant variance connecting chemical and biological space \[[@CR13]\], and that including base models with low predictive power does not add additional predictive signal to improve the modelling of these data sets.Fig. 6RMSE~test~ values obtained with models trained on rv-QAFFP fingerprints calculated using only those base models with R^2^ values on the test set greater or equal than the cut-off value indicated in the x-axis. Each point corresponds to a replicate. Overall, the predictive power on the test set declines as the set of models included to generate the rv-QAFFP is reducedFig. 7RMSE on the test set for predictive models trained on either rv-QAFFP 440 or rv-QAFFP 1360. The results for the 43 data sets and 50 replicates are shown. Overall, it can be seen that the performance of models trained on rv-QAFFP computed using base models with low and high predictive power (i.e., rv-QAFFP 1360) is comparable to the performance of models trained on rv-QAFFP (i.e., rv-QAFFP 440) computed using only base models showing high predictive power

We next analysed the predictive signal provided by each bit in the QAFFP, each one corresponding to a different base model, using the feature importance functionality of Random Forest models \[[@CR64]\]. We did not observe a correlation between the predictive power of base models and the estimated variable importance across the 50 models generated for each descriptor and data set combination (Fig. [8](#Fig8){ref-type="fig"}). The contribution of each descriptor was variable across data sets, and in none of the cases the predictive power was driven by the contribution of few base models, but rather by the combination of weak contribution from many models (Additional file [1](#MOESM1){ref-type="media"}: Figure S6).Fig. 8Analysis of feature importance. The variable importance averaged across 50 replicates for each feature in the QAFFP (i.e., base model) is shown against the predictive power of each base model in cross validation calculated during the training of base models. Overall, a correlation between predictive power and feature importance was not observed

Finally, we sought to investigate whether the activity of some compounds is better modelled by QAFFP in comparison to Morgan2 fingerprints. Such an evidence would support the use of QAFFP instead of, or in addition to, other compound descriptors in predictive bioactivity modeling. To this, we examined the correlation between the errors in prediction on the test set calculated with models trained on either Morgan2 fingerprints, one of the three types of QAFFP considered, or combinations thereof. It was found that 40.1--56.6%, and 73.7--86.2% of the test set instances were predicted with an absolute error in prediction below 0.5 and 1.0 pIC~50~ units, respectively by both Morgan2 and QAFFP-based models (Table [3](#Tab3){ref-type="table"}). Although less than 0.5% of the test set instances were predicted with variable errors in prediction across models trained on different fingerprint types, the error in prediction for some compounds varies \> 2 pIC~50~ units depending on the fingerprint type used for modeling (Additional file [1](#MOESM1){ref-type="media"}: Figures S7, S8). For instance, the error in prediction for compound CHEMBL2420625 is 1.93 pIC~50~ units (σ = 0.29; *n *= 50) for the Morgan2-trained model, whereas the error drops to 0.69 pIC~50~ units (σ = 0.16; *n *= 50) pIC~50~ units for models trained on QAFFP (Additional file [1](#MOESM1){ref-type="media"}: Figure S8).Table 3Percentage of instances in the test set predicted using Morgan2-based and rv-QAFFP-based models showing an Absolute Error in Prediction (AEP) meeting the cut-off values indicated in the headerDatasetAEP Morgan2 and AEP rv-QAFFP 440 ≤ 0.5AEP Morgan2 and AEP rv-QAFFP 440 ≤ 1.0AEP Morgan2 ≥ 1.0 and AEP rv-QAFFP 440 ≤ ≤0.5AEP Morgan2 ≤ 0.5 and AEP rv-QAFFP 440 ≤ ≥ 1.0AEP Morgan2 ≥2.0 and AEP rv-QAFFP 440 ≤ ≤ 1.0AEP Morgan2 ≤ 1.0 and AEP rv-QAFFP 440 ≤ ≥ 2.0AEP Morgan2 ≥ 3.0 and AEP rv-QAFFP 440 ≤≤ 1.0AEP Morgan2 ≤ 1.0 and AEP rv-QAFFP 440 ≤ ≥ 3.0A278049.281.10.71.40.10.30.00.0CCRF-CEM46.378.10.51.70.10.20.00.0DU-14552.4830.41.40.1000HCT-11647.281.30.32.300.200HCT-1540.274.713.80.20.300HeLa49.983.10.51.80.10.200HepG256.686.20.42.30.10.500.1HL-6047.980.90.42.400.400HT-2949.280.90.51.600.100K56244.779.50.52.600.200KB40.174.60.63.10.10.500.1L121042.676.40.52.40.10.200LoVo49.379.80.61.700.100MCF750.182.80.42.80.10.400.1MDA-MB-23153.784.90.31.300.100NCI-H46043.675.60.93.10.10.500.2PC-353.685.10.41.600.100SK-OV-340.673.70.74.10.10.400.1

To assemble the 18 cytotoxicity data sets used here, we included all IC~50~ values for a given cell line satisfying the stringent criteria described in "[Methods](#Sec2){ref-type="sec"}" irrespective of the cytotoxicity assay used. We have previously shown that cytotoxicity measurements might vary considerably cross cytotoxicity assays \[[@CR41]\]; others have shown that different biological conclusions might be obtained depending on the parameterization of the dose--response curves \[[@CR65]--[@CR69]\]. Hence, we anticipate that the performance of QAFFP might be higher when modeling proprietary bioactivity data generated under uniform experimental conditions and data analysis pipelines \[[@CR15], [@CR27]\]. Our results show that compound activity can be modelled on a continuous scale using the predicted activities on an unbiased selection of protein targets as compound descriptors. However, we note in particular that the base models used to generate QAFFP were selected on the basis of the amount of bioactivity data available in ChEMBL only, and on whether they could be satisfactorily modelled using Morgan2 fingerprints. Hence, no biological criteria were considered. As more public data become available, it will be possible to test whether including targets with high network connectivity in pathways involved in cytotoxicity, drug resistance, cell cycle, and other biological processes altered in specific cancer types and diseases, might lead to better modeling of compound activity \[[@CR70]\]. Similarly, using biologically meaningful targets to construct QAFFP might provide a better stratification between active and inactive compounds in bioactivity space, and hence enable the generation of models with higher predictive power \[[@CR33], [@CR70], [@CR71]\]. Another important aspect to consider is that the sensitivity of some cancer cell lines to certain chemicals with well-defined mechanisms of action depends on the modulation of one or few proteins or pathways \[[@CR71]--[@CR76]\]. In such cases, using compound activity on a small set of assays as descriptors, and univariate or low-dimensional models might be sufficient to accurately model drug response \[[@CR33], [@CR77]\]. Here, instead of focusing on specific targets associated to the activity of few compounds, we have considered a data-driven approach that can be applicable to (potentially) any compound irrespective of its mechanism of action.

Conclusions {#Sec9}
===========

This study complements the accompanying paper \[Skuta et al.\], where the performance of QAFFP for similarity searching, compound classification and scaffold hopping is reported. Here, we have performed a comprehensive assessment of the performance of regression models trained on QSAR-derived affinity fingerprints (QAFFP). QAFFP enabled the generation of highly predictive models, with RMSE values in the \~ 0.6--0.9 pIC~50~ units range, which is comparable to the predictive power obtained using Morgan2 fingerprints and physicochemical descriptors, as well as to the uncertainty of heterogeneous IC~50~ data in ChEMBL. This level of performance is in line with the high predictive power obtained with QAFFP in similarity searching, compound classification, and scaffold hopping tasks \[Skuta et al.\]. Notably, QAFFP calculated using base models showing high and moderate performance were more predictive than those trained on QAFFP generated using highly predictive models alone, and likely the increased ability to describe variance in the mapping from chemical to biological space seems to be the cause of this behaviour. To further evaluate the practical utility of QAFFP, future studies will be needed to challenge them in more complex scenarios, including the modeling of the synergistic or antagonistic effect of compound combinations \[[@CR79]--[@CR82]\], and to test whether the integration of QAFFP and cell line profiling data sets (e.g., basal gene expression profiles, or changes in gene expression induced upon compound administration) improves drug sensitivity modeling.
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###### 

**Additional file 1: Figure S1.** Distribution of pIC~50~ values for all data sets modelled in this study. **Figure S2.** Model performance on the test set as a function of the number of trees in the Random Forest models for a random selection of 18 data sets. **Figure S3.** R^2^~test~ values calculated with models trained on each of the 11 descriptor types considered across the 43 data sets modelled in this study (related to Fig. [4](#Fig4){ref-type="fig"}). We trained 50 models for each combination of descriptor type and data set, each time holding a different subset of the data as test set. **Figure S4.** Y-scrambling experiments. R^2^~test~ values calculated for models trained after shuffling the response variable are shown. **Figure S5.** RMSE~test~ values as a function of the fraction of the training data used as test set for all data sets. **Figure S6.** Mean variable importance +/− standard deviation averaged across 50 replicates. Only the top 20 descriptors are shown for each data set. **Figure S7.** Examples of compounds that were predicted with higher error by models trained on Morgan2 fingerprints than by models trained on rv-QAFFP 440. The predictions were calculated on the test set across 50 replicates. The mean and the standard deviation across these 50 replicates are shown. The data set is indicated below the compounds ChEMBL IDs. **Figure S8.** Predicted pIC~50~ values using models trained on the fingerprint type indicated in x-axis, against the predicted pIC~50~ values calculated using models trained using the fingerprint type indicated in the y-axis. The plot shows the predictions for 50 replicates for data set A2780. Similar results were obtained for the other data sets. Overall, it can be seen that the predictions generated by models trained using Morgan2 fingerprints and the rv-QAFFP 440 versions considered are highly correlated across the entire bioactivity range modelled.

###### 

**Additional file 2: Table S1** Value and significance for the coefficients of the linear model used to assess the performance of the 11 descriptor types considered. The code and the 43 data sets used in this study are provided at <https://github.com/isidroc/QAFFP_regression>.
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